Acadia Pharmaceuticals

For decades, we have turned scientific promise into meaningful innovations—reimagining care for patients, putting unmet needs first, and expanding possibilities for families impacted by neurological disorders and rare diseases. Our commercial portfolio includes the first and only FDA-approved treatments for Parkinson’s disease psychosis and Rett syndrome. We are developing the next wave of therapeutic advancements with a robust and diverse pipeline that includes mid- to late-stage programs in Alzheimer’s disease psychosis and Lewy body dementia psychosis, along with earlier-stage programs that address other underserved patient needs.